Dementia in Africa: Current evidence, knowledge gaps, and future directions

Rufus O. Akinyemi1,2,3 | Joseph Yaria3,# | Akin Ojagbemi4,# | Maëlenn Guerchet5 | Njideka Okubadejo6 | Alfred K. Njamnshi7,8 | Fred S. Sarfo9 | Albert Akpalu10 | Godwin Ogbole11 | Temitayo Ayantayo1 | Thierry Adokonou12 | Stella-Maria Paddick13 | David Ndetei14 | Judith Bosche15 | Biniyam Ayele16 | Andrea Damas17 | Motunrayo Coker1 | Lingani Mbakile-Mahlanza18 | Kirti Ranchod19 | Kirsten Bobrow20 | Udunna Anazodo21 | Albertino Damasceno22 | Sudha Seshadri23 | Margaret Pericak-Vance24 | Brian Lawlor25 | Bruce L. Miller26 | Mayowa Owolabi1,2,3 | Olusegun Baiyewu4 | Richard Walker1,27 | Oye Gureje4 | Rajesh N. Kalaria1,28,# | Adesola Ogunniyi1,3,# | on behalf of the African Dementia Consortium (AfDC)

1 Neuroscience and Ageing Research Unit, Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria
2 Centre for Genomic and Precision Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria
3 Department of Neurology, University College Hospital, Ibadan, Nigeria
4 Department of Psychiatry University College Hospital/College of Medicine, University of Ibadan, Ibadan, Nigeria
5 INSERM, Univ. Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST, Limoges, France
6 Neurology Unit, Department of Clinical Sciences, College of Medicine, University of Lagos, Ibadan, Nigeria
7 Department of Neurology, Yaoundé Central Hospital/Faculty of Medicine and Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon
8 Brain Research Africa Initiative (BRAIN), Geneva, Switzerland/Yaoundé, Cameroon
9 Department of Medicine, Kwame Nkrumah University of Science & Technology/Komfo Anokye Teaching Hospital, Kumasi, Ghana
10 Department of Medicine, University of Ghana Medical School/Korle Bu Teaching Hospital, Accra, Ghana
11 Department of Radiology, University College Hospital/College of Medicine/University of Ibadan, Ibadan, Nigeria
12 Department of Neurology, University Teaching Hospital, Parakou, Benin
13 Translational and Clinical Research Institute, Newcastle University/KGateshead Health NHS Foundation Trust, Gateshead, UK
14 Department of Psychiatry, University of Nairobi and African Mental Health and Training Foundation, Nairobi, Kenya
15 Kilimanjaro Christian Medical College, Moshi, Tanzania
16 College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
17 Mirembe Mental Health Hospital, Dodoma, Tanzania
18 Department of Psychology, Faculty of Social Sciences, University of Botswana, Gaborone, Botswana
19 Lufuno Neuropsychiatry Centre, Johannesburg, South Africa
20 Department of Medicine, University of Cape Town, Cape Town, South Africa
21 Lawson Health Research Institute / Department of Medical Biophysics, Western University, London, Ontario, Canada
22 Department of Cardiology, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique
23 Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, Texas, USA
24 John T. Hussman Institute for Human Genomics and the Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami Miller School of Medicine, Miami, Florida, USA
25 Global Brain Health Institute, Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
1 | INTRODUCTION

Globally, Alzheimer’s disease (AD) and other dementias constitute a major public health priority with substantial negative individual, social, and economic impacts.1-2 The current estimates from the World Health Organization (WHO) indicate that by 2050, 150 million persons, representing a 204% increase from 2017, will be living with dementia.3,4 Indications are that the majority of these increases will be found in low- and middle-income countries (LMIC) including within Africa.3-5 Worldwide, dementia is the fifth leading cause of death and the second leading contributor to death from neurological diseases.6 Recent estimates suggest that more than 818 billion USD is spent annually on dementia-related care worldwide and by 2028 the worldwide cost of dementia care is estimated to be > 2 trillion USD.7 These include direct medical and other formal and informal health and social care costs.

The projection that more than 68% of persons with dementia will reside in LMICs by 20505 is largely due to the demographic transition and population growth in the LMICs including certain African countries, which are among the world’s most populous. The burden of dementia is shared by the person; their immediate family; caregivers; and the health, social, legal, and financial systems of the community at large. In Africa, as in many other underserved populations, additional strains on dementia care exist, attributable to globalization, rapid socioeconomic transitions, and the gradual erosion of key informal care systems such as multigenerational family structures, which are the bedrock of dementia care.8 As such, the continent needs to devise robust alternative plans for the care of persons with dementia within the formal health-care sector, taking advantage of global advancements in preventive, therapeutic, and rehabilitative care of the condition.

Currently, there is a dearth of information on the basic and translational science of dementia in Africa. There is paucity of neuroimaging and fluid biomarker studies, and very few neuropathological and genomic studies limited to candidate gene reports in pockets of cohorts. Basic and clinical research in AD and other dementias are also constrained in countries with greater public awareness and affluence. There is therefore a limitation in the capacity for rigorous endophenotyping and the delivery of evidence-based personalized/precision approaches to dementia care, especially in the context of the unique diversity of African genomes and their interactions with the local environment. This review aims to summarize the current epidemiological evidence on dementia in Africa, highlight challenges, identify knowledge gaps, and suggest future research directions and goals.
2 | CURRENT EVIDENCE

2.1 | Epidemiology

More than two-thirds of the world’s population of older people (≥ 65 years old) reside in less developed countries, many of whom are in Africa.9 The prevalence and incidence of dementia increase with age.10 However, despite the projected large increases in the number of persons living with dementia, current estimates of prevalence and incidence of dementia from multiple studies in Africa are among the lowest in the world. While this may be due to numerous factors including low life expectancy in many African nations, it should be noted that dementia data derived from observational studies using similar methodological approaches and designed to reflect the diversity of Africa are still relatively few even though growing. The paucity of data reflects the challenges of conducting quality research in many resource-poor African countries (Figure 1).

2.2 | Incidence

Information on the incidence of dementia in Africa is currently sparse (Figure 1). There are four recent reports on dementia incidence from Western Africa, and one each from Central Africa and Northern Africa. Notably, most of the data on incidence are from one country, Nigeria. Current incidence estimates from Sub-Saharan Africa (SSA) are similar to that for other LMICs at 13.26/1000 person years implying 367,698 new cases each year.11 The Alzheimer’s Disease International (ADI) meta-analysis shows that incidence doubles for every 7.7-year increase in age in SSA.11 For Northern Africa, a recent review on the epidemiology of dementia in the Middle East and North Africa (MENA) estimated a crude incidence of 27/1000 over a 20-year period for Egypt.12 Similar to prevalence, the reported annual incidence rates of dementia in Africa are generally lower than rates reported among populations of older persons living in Europe and North America.13 Differences in diet and burden of cardiovascular risk factors, medical comorbidities, access to quality health care, and mortality have been suggested as possible reasons for the lower incidence of dementia in Africa compared to higher income regions of the world.14 In one study comparing the incidence of dementia and AD in two comparative cohorts of African Americans and Yoruba Nigerians aged 70 years or older and evaluated a decade apart in 1992 and 2001, respectively, the standardized annual incidence rates of dementia and AD were relatively stable in the Yoruba African cohort (dementia: 1.7% vs. 1.4%; AD: 1.5% vs. 1.0%), whereas there was a significant decline among the African Americans (dementia: 3.6% vs. 1.4%; AD: 2.5% vs. 1.3%).15

2.3 | Prevalence

Studies in Africa have generally reported varied but generally lower prevalence of dementia compared to findings in Europe and America.16 Limitations with many African studies include low quality of methods used, types of study settings (i.e., inpatients, outpatients, nursing homes, autopsy), and limited coverage of the different African regions17 (Table 1). The pattern of the findings is such that hospital-based studies report the lowest prevalence estimates of dementia in Africa.17 However, 48% of a sample of nursing home residents in Nigeria met the clinical diagnostic criteria for dementia.18

As highlighted in a systematic review by Mavrodaris et al., variation in dementia prevalence depends on the criteria and methodology used.19 Overall, higher prevalence estimates of up to 20.0% have been reported in community-based studies using different approaches and multiple rating scales for defining dementia.20,21,30 There are also important geographical variations in the prevalence estimates of dementia. The lowest prevalence rate of 2.3% has been reported from Ibadan, Nigeria,22 and Al Kharga, Egypt.23 The reported prevalence of dementia appears low in Western Africa with most studies reporting prevalence ≈ 3%24–26 and much lower than figures above 6% in Central, Eastern, and Southern Africa.21,27–30 Figures from Northern Africa tend to be intermediate and range from 2.3% to 5.1%23,31–34 (Figure 2; Table 1).

2.4 | Mortality

The recent report on dementia in SSA published by ADI included results from four African studies that have estimated dementia mortality risk. The result showed an increased mortality risk with a hazard ratio (HR) ranging from 1.5 (95% confidence interval [CI]:
1.2–1.8)35 to 6.3 (95% CI: 3.2–12.6)36 and an estimate from meta-analysis of HR = 2.3 (95% CI: 1.0–3.5).11 Contrary to expectations of a higher risk of dying from dementia in the developing compared to developed countries, some studies in Africa reported a lower risk of mortality from dementia than has been reported in several middle- and high-income countries.35 Urban dwelling and anthropometric evidence of under-nutrition were independent predictors of dementia mortality in the Ibadan Study of Ageing cohort.35

2.5 Economic cost

Data on the direct costs of dementia in Africa are largely nonexistent. However, it has been estimated that the cost of dementia in 2015 represented 6.2 billion US dollars for SSA, of which 70% is attributable to the cost of informal care most often provided by relatives and families of people living with dementia.11 A limit of this estimate is that it is based on imputations using the countries’ gross domestic product and the medical/social/informal cost distribution from a multicentric study in LMICs from the 10/66 Dementia Research Group. There is a lack of original data regarding health service use and cost of services in African countries, which could inform a better and more precise estimation of the cost of dementia in the region.37

2.6 Risk factors

A number of known risk factors for dementia have been evaluated by various studies in Africa. While the results do not significantly differ from those reported in other regions, the strength of the evidence is limited by the fact that most of these studies were cross-sectional in design. New risk factors for dementia such as air and environmental pollution need further study in Africa. Hence, more longitudinal studies that can inform context-specific interventions are needed from multiple African regions.

2.6.1 Non-modifiable risks

Age is the most consistent non-modifiable risk factor for cognitive impairment and dementia. Various studies have corroborated the known association with both prevalent and incident dementia in the African context.11,12,21,22,38–41 Regarding association with sex, many studies have also reported that dementia and AD are either more prevalent in the female sex,22,24–26,29 or the male sex,42 or have found no association.21 The association with the female sex may be linked to a higher life expectancy and often poorer education.

Using mainly candidate gene approaches, some genetic loci/alleles have been associated with dementia phenotypes in Africa, with the apolipoprotein E (APOE) gene being the most studied (Table 2). Whereas the APOE ε2 allele is protective,43 the APOE ε4 allele increases the risk of AD in Whites44 but not conclusively in indigenous African populations (particularly those in SSA). Older population-based studies showed weak or no association between APOE ε4 and cognitive decline24 or AD,24,45–47 whereas more recent data reported a significant association between APOE ε4 homozygosity48 and incident AD among Yoruba Nigerians.49 It is particularly intriguing that whereas the APOE ε4 allele has been clearly associated with AD in Northern Africa, the association has been nonexistent or rather weak in SSA.50 While gene–environment interactions might influence the link, there is also the plausibility of the existence of novel genetic variants that have stronger genetic contribution to AD biology in SSA populations.8,51 Further studies are therefore needed to explore the geographical disparities in the relative association of the APOE alleles and AD in different African regions, although ancestry-specific genetic factors near APOE have been implicated.52 The APOE ε4 allele has also been linked with mortality23 and white matter integrity in adults with human immunodeficiency virus (HIV) infection.54 Studies from Northern Africa have reported other genetic associations of AD with mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes.55,56 In South Africa, PSEN1 mutation has been reported in a family with early onset AD57 and the CHMP2B polymorphisms in a South African family with frontotemporal
### TABLE 1  Summary of community-based epidemiological studies of dementia in Africa

<table>
<thead>
<tr>
<th>Author/site, country</th>
<th>Year</th>
<th>Criteria</th>
<th>Sample (n)</th>
<th>Age (years)</th>
<th>Prevalence</th>
<th>Dementia</th>
<th>AD</th>
<th>VaD</th>
<th>Identified risk factors</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>West Africa</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hendrie et al.22/</td>
<td>1995</td>
<td>DSM III-R</td>
<td>2494</td>
<td>≥ 65</td>
<td>2.3%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No consideration for educational status. Cultural bias in diagnosis. High rate in Indianapolis cohort. Age was determined using historical landmarks.</td>
</tr>
<tr>
<td>Ibadan, Nigeria</td>
<td></td>
<td>ICD-10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogunniyi et al.16/Ibadan,</td>
<td>1997</td>
<td>DSM III-R</td>
<td>2494</td>
<td>≥ 65</td>
<td>64.3%</td>
<td>28.6%</td>
<td></td>
<td></td>
<td></td>
<td>Age was determined using historical landmarks. High illiteracy rates. No radiological confirmation.</td>
</tr>
<tr>
<td>Nigeria</td>
<td></td>
<td>ICD-10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hall et al.63/Ibadan,</td>
<td>2006</td>
<td>DSM III-R</td>
<td>1075</td>
<td>≥ 70</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dyslipidemia.</td>
<td>Small number of AD cases. Survivor bias as most of the attrition from earlier cohort were due to mortality. Criteria for control group uncertain. Cross-sectional design not appropriate to determine association. Some cross-sectional studies.</td>
</tr>
<tr>
<td>Nigeria</td>
<td></td>
<td>ICD 10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ochayi and Thatcher78/Jos</td>
<td>2006</td>
<td>CSID</td>
<td>280</td>
<td>≥ 65</td>
<td>6.4%</td>
<td></td>
<td></td>
<td></td>
<td>Age, female sex, BMI, NSAIDs</td>
<td>Possible over-estimation of dementia rate due to one-stage process used. Wide confidence intervals for estimates. Estimated ages. Cross-sectional design.</td>
</tr>
<tr>
<td>Nigeria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guereje et al.20/Southwest</td>
<td>2006</td>
<td>10-WDRT</td>
<td>2152</td>
<td>≥ 65</td>
<td>10.1%</td>
<td></td>
<td></td>
<td></td>
<td>Age, female sex, lifetime history of alcohol use</td>
<td>Cross-sectional design. Incomplete information about disabilities.</td>
</tr>
<tr>
<td>Nigeria</td>
<td></td>
<td>DSM IV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guerchet et al.24/Djidja,</td>
<td>2009</td>
<td>DSM-IV</td>
<td>514</td>
<td>≥ 65</td>
<td>2.6%</td>
<td>53.8%</td>
<td>7.7%</td>
<td></td>
<td>Age</td>
<td>Self-reported education. Informal age confirmation. Cross-sectional design. Low proportion of subject schooled. No radiological confirmation.</td>
</tr>
<tr>
<td>Benin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yusuf et al.26/Zaria,</td>
<td>2011</td>
<td>DSM IV</td>
<td>322</td>
<td>≥ 65</td>
<td>2.8%</td>
<td>66.7%</td>
<td>33.3%</td>
<td></td>
<td>Age</td>
<td>One-stage selection. No radiological confirmation. Sub-section of CSI-D used. Neuropsychology test do not have adjusted normative values for illiterate population. Relatives not involved to confirm details.</td>
</tr>
<tr>
<td>Nigeria</td>
<td></td>
<td>ICD-10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paraiso et al.25/Cotonou,</td>
<td>2011</td>
<td>DSM-IV</td>
<td>1162</td>
<td>≥ 65</td>
<td>3.7%</td>
<td></td>
<td></td>
<td></td>
<td>Age, female sex</td>
<td>Sub-section of CSI-D used. Neuropsychology test do not have adjusted normative values for illiterate population. Relatives not involved to confirm details.</td>
</tr>
<tr>
<td>Benin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guereje et al.37/Southwest</td>
<td>2011</td>
<td>10-WDRT</td>
<td>1225</td>
<td>≥ 65</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Age, sex, poor economic status, rural living, social isolation</td>
<td>Preponderance of persons with little or no education. Use of 10-WDRT Non-cross-sectional studies.</td>
</tr>
<tr>
<td>Nigeria</td>
<td></td>
<td>CHIF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Akinwumi et al.41/Ibadan and Abeokuta, Nigeria</td>
<td>2014</td>
<td>DSM-IV</td>
<td>143 Stroke survivors</td>
<td>≥ 65</td>
<td>8.4%</td>
<td></td>
<td></td>
<td></td>
<td>Age, low education, medial temporal lobe atrophy, pre-stroke cognition</td>
<td>Modest sample size. Incomplete neuroimaging.</td>
</tr>
<tr>
<td>Author/site, country</td>
<td>Year</td>
<td>Criteria</td>
<td>Sample (n)</td>
<td>Age (years)</td>
<td>Prevalence</td>
<td>Identified risk factors</td>
<td>Limitations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>------</td>
<td>----------</td>
<td>------------</td>
<td>-------------</td>
<td>------------</td>
<td>------------------------</td>
<td>-------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogunniyi et al.42/Lalupon, Nigeria</td>
<td>2016</td>
<td>DSM-IV</td>
<td>613</td>
<td>≥ 65</td>
<td>2.9% 58.8% 11.7%</td>
<td>Age</td>
<td>Lack of neuroimaging. Identification of treatable conditions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ojagbemi et al.35/Southwest, Nigeria</td>
<td>2016</td>
<td>10-WDRT CHIF</td>
<td>2149</td>
<td>≥ 65</td>
<td>Age, sex, socioeconomic status, pre-existing cognitive decline, occupational complexity</td>
<td>Inaccurate survival data. Attrition. Small size of dementia mortality sample</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarfo et al.40/Kumasi, Ghana</td>
<td>2017</td>
<td>DSM-IV</td>
<td>147 (Stroke survivors)</td>
<td>Age, education, functional ability</td>
<td>3.2% 64.3% 21.4%</td>
<td>Age, living alone, low vegetable intake</td>
<td>Not generalizable. Verbal report of vascular factors. Participants may have benefitted from having a better socioeconomic status and better access to health care than the overall older population. Sample size was small. High level of refusals. Use of the brief version of the CSID also carries some limitations.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adoukonou et al./ Parakou, Benin</td>
<td>2020</td>
<td>DSM-IV-TR</td>
<td>440</td>
<td>≥ 50</td>
<td>3.2% 64.3% 21.4%</td>
<td>Age, living alone, low vegetable intake</td>
<td>Not generalizable. Verbal report of vascular factors. Participants may have benefitted from having a better socioeconomic status and better access to health care than the overall older population. Sample size was small. High level of refusals. Use of the brief version of the CSID also carries some limitations.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central Africa</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guerchet et al.27/Bangui, CAR</td>
<td>2010</td>
<td>DSM-IV</td>
<td>496</td>
<td>≥ 65</td>
<td>8.1% 82.5% 17.5%</td>
<td></td>
<td>DSM-I-V underestimate. No radiological confirmation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guerchet et al.27/Brazzaville, Congo</td>
<td>2010</td>
<td>DSM-IV</td>
<td>520</td>
<td>≥ 65</td>
<td>6.7% 68.6% 31.4%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guerchet et al.65/Bangui CAR and Brazzaville, Congo</td>
<td>2012</td>
<td>DSM-IV</td>
<td>977</td>
<td>≥ 65</td>
<td>7.6%</td>
<td>Age, female sex, hypertension, peripheral artery disease, low BMI, depression, lack of education</td>
<td>High rate of missing data. Cross-sectional design. Absence of APOE genotyping. No radiological confirmation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>East Africa</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Longdon et al.29/Kilimanjaro, Tanzania</td>
<td>2013 2014</td>
<td>DSM-IV</td>
<td>1198</td>
<td>≥ 70</td>
<td>6.4% 48.7% 41.0%</td>
<td>Diabetes</td>
<td>No radiological confirmation. Incomplete radiological and laboratory investigations. Too little number for subtypes. Attrition. Non-medically trained census enumerators.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paddick et al.63/Kilimanjaro, Tanzania</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mubangizi et al.30/Rural Southwest, Uganda</td>
<td>2020</td>
<td>Brief CSID</td>
<td>400</td>
<td>≥ 60</td>
<td>20.0%</td>
<td>Age. But having some education, exercise and ventilated kitchen were protective</td>
<td>No structured clinical interviews. Brief CSID used. Early and midlife exposure variables were measured by self-reporting.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yoseph et al.162/Kilimanjaro, Tanzania</td>
<td>2021</td>
<td>DSM-V</td>
<td>3011</td>
<td>≥ 70</td>
<td>8.9%</td>
<td></td>
<td></td>
<td>(Continues)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**TABLE 1** (Continued)

<table>
<thead>
<tr>
<th>Author/site, country</th>
<th>Year</th>
<th>Criteria</th>
<th>Sample (n)</th>
<th>Age (years)</th>
<th>Prevalence</th>
<th>Identified risk factors</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dementia</td>
<td>AD</td>
<td>VaD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South Africa</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramlall et al/Nursing Homes, South Africa</td>
<td>2013</td>
<td>DSM-IV-TR</td>
<td>140</td>
<td>≥ 60</td>
<td>7.9%</td>
<td>40.0%</td>
<td></td>
</tr>
<tr>
<td>De Jager et al13/ Amatole District, South Africa</td>
<td>2017</td>
<td>CSID</td>
<td>1394</td>
<td>≥ 65</td>
<td>11.0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>North Africa</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Farrag et al.34/ Assiut Governorate, Egypt</td>
<td>1998</td>
<td>DSM-III R</td>
<td>2000</td>
<td>≥ 60</td>
<td>4.5%</td>
<td>53.0%</td>
<td>22.9%</td>
</tr>
<tr>
<td>El Tallawy et al.23/ Al Kharga District, Egypt</td>
<td>2012</td>
<td>DSM-IV-TR</td>
<td>8173</td>
<td>≥ 50</td>
<td>2.3%</td>
<td>51.2%</td>
<td>28.7%</td>
</tr>
<tr>
<td>El Tallawy et al.32/ Al-Quseir city, Egypt</td>
<td>2014</td>
<td>DSM-IV</td>
<td>4329</td>
<td>≥ 50</td>
<td>3.8%</td>
<td>48.3%</td>
<td>36.8%</td>
</tr>
<tr>
<td>Khedr et al33/ Qena Governorate, Egypt</td>
<td>2015</td>
<td>DSM-IV</td>
<td>619</td>
<td>≥ 60</td>
<td>5.1%</td>
<td>34.3%</td>
<td>25.7%</td>
</tr>
</tbody>
</table>

dementia (FTD).\textsuperscript{58} Newer studies have also reported associations between cognitive impairment and carotid artery plaques.\textsuperscript{69} Hyper-tension and type 2 diabetes were also found to be associated comor-bidities in Nigerian hospital–based dementia cohorts.\textsuperscript{70–72} Other less established risk factors that have also been shown to increase the risk of dementia in Africa include homocysteine\textsuperscript{73} and folate.\textsuperscript{74}

As shown in the extant dementia literature particularly from the West, studies from Africa have also demonstrated an association between lower educational attainment and increased dementia risk.\textsuperscript{41,65,75} Based on the cognitive reserve hypothesis,\textsuperscript{76–78} it is suggested that education might interfere with the phenotypic expression of dementia. However, other studies have reported a lack of association between education and dementia on the continent.\textsuperscript{22,29,79,80} Nonetheless, it is noted that the majority of older Africans included in these studies had no formal education lasting 7 years and only a minority had a few years of formal education. It is likely that this low level of formal education may not be an appropriate signature of cognitive reserve. Indeed, many older Africans—even centenarians—despite having no formal Western education play key social roles and have communal responsibilities that better reflect their cognitive ability and likely this plays a role in maintaining cognitive reserve. Traditional systems of learning that can also improve cognitive abilities need to be consid-ered. As such, one should consider the limitations and appropriateness of directly translated cognitive scales that have been used in the past in interpreting the association. Fortunately, newer context-sensitive tools are being developed for better cognitive evaluation in the region to address these observations.\textsuperscript{81–83}

A review of the literature from Africa demonstrates limited evidence on the relationship between lifestyle factors such as diet, physical activity, smoking, and alcohol and cognitive impairment and dementia. Anthropometric markers of malnutrition such as reduced body mass index,\textsuperscript{65,84} low arm muscular circumference, low mid-upper arm circumference,\textsuperscript{84–86} and lower consumption of oily foods have been associated with dementia.\textsuperscript{85} Undernutrition, especially with low con-sumption of an oleaginous diet was associated with prevalent dementia in a study involving two countries from Central Africa,\textsuperscript{17,85} while a history of smoking, current smoking, and weight loss were linked to incident dementia in Nigeria.\textsuperscript{84} Pre-stroke daily fish intake was found to be protective against cognitive impairment among stroke survivors.\textsuperscript{41} It has also been suggested that the lower risk of dementia among Yoruba Nigerians is related to low levels of saturated fat and high fiber content in their traditional diet, which consists of yam tubers (\textit{Dioscorea rotundata}), grains, vegetables, and fish.\textsuperscript{64} Fiber has many beneficial effects, including alteration of the gut microbiota and consequent implication for the gut–brain axis and related brain disorders. Based on data from the WHO’s Study on Global Ageing and Adult Health (SAGE), a cross-sectional, community-based study conducted in South Africa demonstrated an association between food insecurity and cognitive impairment.\textsuperscript{87} However, findings from the two studies on the link between alcohol and dementia were contradictory.\textsuperscript{85,88} The importance of lifestyle and environmental factors and their interaction with genetic factors has been elucidated in comparative cross-national studies.\textsuperscript{89} The care structure for older persons in traditional African societies provides a rich social support network with older persons often living in multigenerational settings, although this is now been eroded by migration, urbanization, and globalization.\textsuperscript{90} The effect of these changes in care structure on the trends of cognitive

FIGURE 2  Prevalence of dementia in Africa. Heat map showing wide range of dementia prevalence in African countries determined over the past 25 years. Dementia prevalence studies have also been conducted in Senegal and Kenya, but the data are not published yet.

2.6.2  Modifiable risks

Several studies have demonstrated associations between traditional cardiovascular risk factors—hypertension,\textsuperscript{61,62} type 2 diabetes,\textsuperscript{26,63} dyslipidaemia,\textsuperscript{64} and peripheral arterial disease,\textsuperscript{65,66} and cognitive impairment and dementia phenotypes.\textsuperscript{67} While peripheral arterial disease and systemic hyperten-sion were linked to prevalent dementia in Central and West Africa, respectively,\textsuperscript{17} high total cholesterol and low-density lipoprotein were predictors of incident dementia in Nigeria.\textsuperscript{64} Mild cognitive impairment (MCI) is a precursor of dementia. In one community-based study from Lalupon, southern Nigeria, MCI was associated with mean arterial pressure (MAP) and pulse pressure,\textsuperscript{68} while a Ugandan community–based study found an association between cognitive impairment and carotid artery plaques.\textsuperscript{59} Hyperten-sion and type 2 diabetes were also found to be associated comor-bidities in Nigerian hospital–based dementia cohorts.\textsuperscript{70–72} Other less...
impairment and dementia in Africa deserve further research focus. Available data, however, showed that living with others was protective against dementia in the Ibadan cohort of the Ibadan–Indianapolis Dementia Project91 while low social network92 and poor social engagement38 were risk factors for prevalent and incident dementia in a Senegalese and another Nigerian study, respectively. The role of sleep, hearing loss, head trauma, air pollution, and environmental toxins such as lead have not been studied as potential risk factors for dementia in the African context.

The role of in utero and early life exposure in dementia occurrence has been the focus of several studies in high-income countries,93,94 but these have not been widely explored in Africa. Well-designed longitudinal studies to explore the role of early life factors will require considerable funding and expertise. Pilleron et al., however, reported a significant association between the death of one parent during childhood and dementia in late life from studies conducted in the Central African region.95

Substantial evidence abounds demonstrating HIV as a cause of neurocognitive disorders with about two-thirds of people living with HIV diagnosed with probable HIV-associated neurocognitive disorder (HAND).96–102 With more than 11.3 million human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) patients affected by HAND,96 it has been suggested that the burden of HAND in Africa is likely to rank among the highest of any region in the world. There are several reasons for the high burden of HAND on the continent. First, Africa has the highest HIV/AIDS burden in the world. Second, in many parts of Africa late presentation of HIV is rife with related advances in infection characterized by severe immunosuppression, which directly predisposes one to HAND.101,102 HIV also increases the risk of atherosclerotic strokes104 and of tuberculosis including tuberculous meningitis and tuberculomas that indirectly increase risk of cognitive decline and dementia. Furthermore, the development of new genetic recombinant forms of HIV1 as well as its genetic variation in genetic recombinant forms of HIV1 as well as its genetic variation in genetic recombinant forms of HIV1 as well as its genetic variation genotypic treatment and infection by HIV was associated with cognitive decline.107

The role of toxoplasmosis infection in dementia emphasizes the fact that parasitic infectious agents might be particularly important contributors to cognitive impairment and dementia in Africa.107 A recent case-control study reported a higher prevalence of cognitive impairment in people with epilepsy, particularly decreased executive function and verbal fluency, than in people without epilepsy in an onchocerciasis-endemic area of Cameroon.108 Evidence from children with retinopathy-positive cerebral malaria suggests some cognitive impairment.109,110 Longitudinal studies are necessary to delineate the role of parasitic diseases in cognitive function and dementia in Africa.

### TABLE 2 Candidate gene studies for dementia phenotypes in Africa

<table>
<thead>
<tr>
<th>Authors (year)</th>
<th>Gene name</th>
<th>Study population</th>
<th>Salient findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osuntokun et al. (1995) 44</td>
<td>APOE ɛ4</td>
<td>Yoruba Nigerian</td>
<td>No association was reported between APOE ɛ4 alleles and AD</td>
</tr>
<tr>
<td>Lane et al. (2003) 52</td>
<td>APOE ɛ4</td>
<td>African American and Yoruba Nigerian</td>
<td>No association was observed between APOE ɛ4 alleles, age, and mortality risk among the Yoruba Nigerians.</td>
</tr>
<tr>
<td>Heckmann et al. (2004) 56</td>
<td>PSEN1</td>
<td>Southern Africa</td>
<td>PSEN1 mutations associated with early onset AD but no effect of APOE ɛ4</td>
</tr>
<tr>
<td>Gureje et al. (2006) 45</td>
<td>APOE ɛ4</td>
<td>Nigerian</td>
<td>Lack of association between APOE ɛ4 and AD</td>
</tr>
<tr>
<td>Chen et al. (2008) 46</td>
<td>APOE ɛ4</td>
<td>Kenyan</td>
<td>Lack of association between APOE ɛ4 and AD</td>
</tr>
<tr>
<td>Guerchet et al. (2009) 53</td>
<td>APOE ɛ4</td>
<td>Beninoise</td>
<td>No association between APOE ɛ4 and cognitive decline</td>
</tr>
<tr>
<td>Hoare et al. (2013) 53</td>
<td>APOE ɛ4</td>
<td>South African</td>
<td>APOE ɛ4 is associated with memory impairment and white matter integrity in HIV-positive individuals</td>
</tr>
<tr>
<td>El Kadmiri et al. (2014) 54</td>
<td>APP</td>
<td>Moroccan</td>
<td>7 novel mutations (frameshift mutations) in the APP gene on exons 16 and 17 had genetic contributions to AD</td>
</tr>
<tr>
<td>Hendrie et al. (2014) 48</td>
<td>APOE ɛ4</td>
<td>African Americans and Yoruba Nigerians</td>
<td>One or two copies of APOE ɛ4 allele is/are significant risk for both AD and cognitive decline in African Americans. Only homozygous carriers of the APOE ɛ4 among Yoruba Nigerians had a significant risk factor for AD but not cognitive decline</td>
</tr>
<tr>
<td>Fekih-Mrissa et al. (2017) 59</td>
<td>PAI-1</td>
<td>Tunisian</td>
<td>Variants of PAI-1 hAd significantly increased risk for AD. Homozygotes are at higher risk while female sex was also at increased risk.</td>
</tr>
<tr>
<td>Landoulsi et al. (2018) 58</td>
<td>TREM2</td>
<td>Tunisian</td>
<td>TREM2 has no association with late onset AD which has significant risk in White populations</td>
</tr>
<tr>
<td>Haithem et al. (2018) 57</td>
<td>APOE, ACE1, PON1</td>
<td>Tunisian</td>
<td>All studied genes had polymorphisms associated with dementia risk individually and collectively with a cumulative and synergistic effect</td>
</tr>
</tbody>
</table>

Abbreviations: ACE1, angiotensin-converting enzyme; AD, Alzheimer’s disease; APOE, apolipoprotein E; APP, amyloid precursor protein; CHMP2B, charged multivesicular body protein 2B; HIV, human immunodeficiency virus; PAI 1, plasminogen activator inhibitor-1; PON1, serum paraoxonase and arylesterase 1; PSEN1, presenilin 1; PSEN2, presenilin 2; TREM2, triggering receptor expressed on myeloid cells 2.
2.7 | Dementia subtypes in Africa

AD and vascular cognitive impairment and dementia (VCID) remain the most commonly reported dementia phenotypes (Table 1). A report from the Ibadan–Indianapolis dementia study suggests that in a densely populated urban community in Ibadan, southwestern Nigeria, only 12% of all new cases of dementia between 1995 and 2001 received a diagnosis of vascular dementia (VaD) based on Diagnostic and Statistical Manual Revised Third Edition (DSM III-R) and International Classification of Diseases 10th Revision (ICD-10) criteria. In a recent systematic review, the proportion of VCID in multiple African studies ranged between 17% and 41% for all phenotypes of dementia depending on the type of study sample. Other dementia phenotypes reported in Africa include FTD; dementia with Lewy bodies (DLB); Parkinson’s disease dementia (PDD); Huntington disease, and sickle cell disease (SCD). However, confirmation of dementia subtype is only definitive after post mortem neuropathologic examination and this level of diagnostic certainty has not been achieved in existing studies from Africa with the exception of the first reported case of DLB. SCD is well known to predispose to vascular brain injury, particularly silent cerebral infarction (SCI), which is often associated with cognitive impairment. Studies in Cameroon and Nigeria have revealed that executive function—in particular, attention and working memory—are severely affected in SCD children with high cerebral blood flow velocities. A recent comparative magnetic resonance imaging (MRI) study in Tanzania showed that SCI, vasculopathy, and hemoglobin are independent risk factors for diffuse white matter injury in children with SCD.

2.8 | Living with dementia in Africa

A common problem in Africa and probably other LMICs for persons living with dementia is grappling with stigmatization. Limited studies have reported that stigmatization is rooted in belief systems, commonly cultural or supernatural, where persons with dementia are thought to be witches. Even though the role of traditional healers, community leaders, and faith healers in health promotion cannot be overlooked, there is nevertheless evidence that these community opinion leaders commonly do not view dementia as a specific disease but rather a feature of normal aging. Occasionally, caregivers and even health-care workers hold similar beliefs, an observation that suggests a need for education of both the general population and health-care workers. There is evidence in support of higher educational attainment being associated with less stigmatizing attitudes. The need for education is particularly key, as caregivers are unlikely to seek health interventions without adequate information. In Nigeria, about one-third of people feel that even individuals living with dementia would prefer not to know or let others know their disease status.

To relieve caregiver burden, formal home care is a viable option in high-income countries but not in Africa. Negative attitudes to formal care exist among some family members and in some societies irref-
3 | GAPS AND FUTURE DIRECTIONS

3.1 | Cognitive evaluation in Africa

Robust cognitive tools that are culture-sensitive with excellent psychometric properties and resistant to the differences due to effects of education and languages are needed for deployment across multiple regions of Africa. The need to use cognitive and functional assessment instruments that are culturally appropriate and adopt common approaches to clinical evaluation of dementia across African countries cannot be overemphasized. This is because comparison of dementia rates from different studies may be fraught with difficulties due to variations in assessment tools and approaches. Various investigators have tried to improve on neuropsychological tests used on the continent with a view to adjusting for the peculiarities of the environment, ease of administration, and educational status. The Community Screening Instrument for Dementia (CSI-D) is a screening tool that was developed for settings with low education.\(^{146,147}\) It has been deployed in several dementia epidemiological studies in SSA and the 10/66 dementia research group has developed a shorter version of it with excellent psychometric properties.\(^{148}\) The Rowland Universal Dementia Assessment Scale (RUDAS) has been validated for dementia screening in Arabic-speaking populations.\(^{149}\) The Intervention for Dementia Assessment Scale (RUDAS) has been validated for dementia screening in Arabic-speaking populations.\(^{149}\) The Intervention for Dementia in Elderly Africans (IDEA) Cognitive Screen\(^{85}\) is a six-item instrument that was more recently developed with components derived from the CSI-D (items 1–4). Item 5 was taken from the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) 10-word recall test, while the sixth item was designed to measure praxis and consists of a matchstick design test originally developed by Baiyewu et al.\(^{150}\) The IDEA Cognitive Screen therefore includes measures of delayed recall, orientation, two measures of executive function, verbal fluency and abstract reasoning, praxis, and long-term memory. No items were included requiring reading, writing, drawing, or calculation to reduce possible educational bias.\(^{81,82}\) It has been validated in Nigeria (Yoruba language) and Tanzania (Swahili language) with excellent psychometric properties including the area under the receiver operating characteristic curve (AUROC) of 0.99 in Nigeria and 0.91 in Tanzania.\(^{81,83}\) The cut-off score is < 7 for possible dementia. The IDEA cognitive screen was used to conduct a dementia prevalence study in Lalupon near Ibadan, Nigeria, and obtained rates that were largely similar to previous rates obtained (using the CSI-D) in the Ibadan–Indianapolis Dementia Project.\(^{42}\) The International HIV Dementia Scale, which was developed in Uganda, has been used as a screening tool for HAND in several African countries.\(^{151,152}\)

The next important step for promoting reliable cognitive evaluation in Africa is the development of normative data across the lifespan, based on the validated culturally sensitive neuropsychological test batteries and screening instruments. Examples of normative data have been reported from Cameroon in the pediatric and adult populations.\(^{99,153}\)

For functional assessment, the Clinician Home-based Interview to assess Function (CHIF) was developed and validated by the Indianapolis–Ibadan dementia research group.\(^{154}\) The IDEA study Instrumental Activities of Daily Living (IDEA–IADL) was also recently developed and validated among rural-dwelling Tanzanians. It had an AUROC of 0.896 for DSM-IV dementia and 0.937 when used in conjunction with the IDEA Cognitive Screen, with no bias for age, sex, or education.\(^{155}\) A shorter version, the three-item IDEA-IADL questionnaire, has also been validated for evaluation of instrumental activities of daily living.\(^{156}\) The Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) has been adapted for low literacy and has good psychometric properties.\(^{157}\) The IDEA-IADL App-Based Cognitive Screening instrument mobile application has now been developed and validated among non-specialist rural community workers. The AUROC was 0.78 with good sensitivity and fair specificity.\(^{158}\) In Central Africa, the Central African Daily Functioning Interference Scale (CA-DFI), a 10-item scale, has also been developed with psychometric properties supporting the reliability and internal validity of the CA-DFI scale as a promising tool for functional assessment in the elderly for the diagnosis of dementia in Central Africa.\(^{159}\)

3.2 | Tracking epidemiological trends

African populations are aging rapidly such that by the year 2050, 212 million older persons 60 years of age and older will be residing on the continent, in keeping with trends in other LMICs.\(^{160}\) Concomitant with this is a projected increase in the prevalence of aging-associated disorders of the brain such as AD and PD. Hence, more epidemiological studies are needed in Africa that will accurately track the secular trends of cognitive impairment and dementia and dementia subtypes in Africa. Community-based studies in Tanzania have reported worsening cognitive decline over 2 years of follow-up\(^{161}\) and increased prevalence of dementia from 6.4% to 8.9% in a rural cohort of older persons > 70 years over a 9-year interval and using the same methods of cognitive assessment.\(^{162}\) This is in contrast to declining trends of dementia reported in high-income countries. Over the years, there has been improvement in dementia epidemiological studies and results suggest an increasing prevalence.\(^{11}\) Increasing prevalence may also suggest greater awareness of dementia in Africa. Other potential, but less studied, sources of variation in prevalence estimates of dementia in Africa include genetic predisposition, lifestyle factors, urban versus rural distribution of study participants, differences in literacy levels, and changes in the age structure of the studied population. Tracking epidemiologic trends provides relevant data needed to inform identification of specific modifiable risk factors for cognitive impairment and dementia that can inform the development of culturally appropriate interventions and the formulation of elderly-friendly policies in African countries.\(^{11,161}\)

3.3 | Insights from neuropathologic evaluation

Accurate phenotyping of dementia subtypes depends on neuropathologic techniques as the gold standard. Although AD is typically characterized by the presence of amyloid plaques and neurofibrillary tangles,
concomitant vascular and/or neurodegenerative pathologies are often detected and produce mixed phenotypes. For example, in a community-based autopsy cohort, approximately 60% of patients with clinical diagnoses of AD-type disease were in fact affected by vascular disease pathology, TDP-43, or Lewy body pathology rather than plaques and tangles.\(^{163}\) Clinicopathological studies are therefore critical in shaping our understanding of the etiology, natural history, and mechanisms of disease and to help in formulating the frameworks necessary for the discovery of new therapeutic and preventative interventions.\(^{123}\)

In Africa, a post mortem study of brain tissue of neurologically normal Nigerian Africans showed incidental Lewy body pathology burden similar to figures that were then reported among individuals of European ancestry from the UK and United States.\(^{164}\) The significance of this finding was the suggestion that the correspondence of the frequency of Parkinsonian pre-symptomatic neuropathology (and indirectly the risk of PD) in Nigerian Africans and Whites in the UK and United States might indicate similarity in the predisposition to PD, while the disparity in prevalence (lower in Nigerian Africans) might be attributable to lower life expectancy in the latter.\(^{165}\) This also implies that as African populations age, the prevalence of PD and PD dementia might rise in parallel. However, in an autopsy survey of 198 brains of Nigerians aged 40 years and above (including 45 individuals [23%] who were above 65 years of age) to determine the occurrence of pathological hallmarks of AD, findings showed mild cortical neuronal loss and absence of neurofibrillary tangles, senile plaques, and amyloid angiopathy—characteristic pathological features hallmarks of AD.\(^{166}\) Clinically at that time, dementia was rather rare.\(^{167}\) A similar post mortem study on non-demented elderly East Africans reported significant neocortical amyloid beta (A\(_\beta\)) deposits and tau protein reactive neurofibrillary tangles evident in the hippocampus in 15.2% and 12.5% of the subjects, respectively, similar to findings in age-matched elderly White control subjects from Cleveland, United States.\(^{168}\)

Other studies involving multiracial populations of North Americans have reported racial disparities in the epidemiology and neuropathology of cognitive impairment and dementia. In a report from the Rush Study, Black subjects were less likely to have AD pathology as a single dementia pathology compared to White subjects (19.5% vs. 42.0%), but were more likely to have AD pathology mixed with an additional pathology (70.7% vs. 50.6%) particularly AD pathology and Lewy bodies, and AD pathology, Lewy bodies, and infarcts. Furthermore, Black subjects also had more severe arteriolar sclerosis and atherosclerosis.\(^{169}\) Similarly, a recent multicultural Brazilian neuropathological study showed a comparable reduction in AD pathology but higher vascular pathology in the brains of subjects of African ancestry.\(^{170}\)

### 3.4 Unravelling the genetic architecture

The observations reported above beg the question of whether there is a protective gene at play that mitigates the amyloid depositing effect of APOE ε4 in African ancestry populations. This lack of clarity is due to the fact that little is yet known about the genetic architecture of AD among indigenous Africans and there is inconsistency in the reported association of AD with APOE ε4 allele among Africans.\(^{8,46,49,50}\) Even though Africa is the origin of modern humans and harbors the greatest genetic diversity in global populations only a fraction of the genetic diversity among Africans has been surveyed with < 2% of genome-wide association studies (GWAS) comprising African data.\(^{171}\)

In a recent high-depth study of African genomes aimed at further exploration of African genomic diversity, whole-genome sequencing analyses were performed on 426 individuals from 50 ethnolinguistic groups under the aegis of the Human Health and Heredity in Africa (H\(^3\)Africa) Consortium. The study found more than 3 million previously undescibed genetic variants.\(^ {172}\) The implications of these observations are enormous for understanding the genetic basis of cognitive impairment and dementia in African ancestry and global populations. Thus, greater representation of indigenous Africans in dementia genomic research including GWAS and whole exome or whole genome sequencing approaches will enhance diversity and inclusiveness and enable novel insights into the biology of brain aging, cognition, AD, and other phenotypes. In addition, fine mapping of loci and variants already described will be enhanced to pinpoint precise causal genetic variants.\(^ {172}\) Furthermore, such studies will facilitate translational genomics: development of Afrocentric polygenic risk scores; and unravel new pathways, biomarkers, and drug targets for the enhancement of precision/personalized dementia care. It will also improve our understanding of disparities in dementia phenotypes, risk factors, and outcomes.\(^ {122,174,175}\) Furthermore, such efforts will be in consonance with the US National Dementia Plan to prevent and effectively treat AD and AD-related dementias (ADRDs) by 2025\(^ {1}\) and the National Academy of Medicine recommendation to use global health research to benefit Americans and global populations.\(^ {176}\)

### 3.5 Fluid, neuroimaging, and other biomarkers

Of all the causes of primary dementia worldwide, AD and VCI account for 70% to 80%, the other major causes being FTD, PD dementia, and Lewy body dementia (LBD).\(^ {142}\) All primary dementias except VCI are due to neurodegenerative proteinopathies—misfolded protein form inclusion bodies that are toxic to the neurons and implicated in neuroinflammation, glial reaction, and neurodegeneration. A\(_\beta\) (AD), tau protein (AD, FTD, cortico-basal degeneration, and progressive supranuclear palsy), TAR DNA-binding protein 43 (TDP-43; frontotemporal lobar degeneration [FTLD]), RNA-binding Fused in Sarcoma (FUS) (FTLD), and alpha-synuclein (PDD, LBD) are the main proteins elucidated and the neuropathological process initiation often precedes the recognizable clinical expression of disease by several years.\(^ {142}\)

Recent studies have highlighted the role of biomarkers—to predict the likelihood of progression to dementia from MCI (cerebral amyloid angiopathy, mesial temporal lobe atrophy on MRI), to confirm clinical diagnosis, and standardize clinical research as clearly captured in the recent National Institute on Aging-Alzheimer’s Association (NIA-AA) AD Diagnostic Criteria.\(^ {174}\) There are major advances in imaging and fluid biomarkers particularly in AD neurobiology. Cerebrospinal fluid (CSF) biomarkers, including A\(_\beta\)1-42, phosphorylated A\(_\beta\)42, and tau protein have been used to stratify patients with AD, LBD, and controls, to rule in or rule out AD, and to predict progression from MCI to AD.\(^ {177}\)

"..."
(p-tau)181, and total (t-tau) tau are of diagnostic significance. CSF Aβ1-42 and positron emission tomography (PET) amyloid imaging with Pittsburgh Compound B (PiB) are markers of brain Aβ deposition, whereas increased levels of CSF t-tau and p-tau, hypometabolism on fluoro-deoxyglucose PET scan, and atrophy on structural MRI scan are markers of neurodegeneration.142,175 More recent data have revealed the utility of blood p-tau181 as a potential diagnostic marker.177,178

A recent meta-analysis found that cerebrospinal fluid t-tau and p-tau181 were consistently lower in Black than White individuals, in samples with normal cognition or with MCI/dementia.179 This suggests that racial differences should be taken into consideration in interpreting differences in biomarker levels in the dementia phenotypes among individuals of different ancestries. For the other dementia phenotypes, there are also useful neuroimaging modalities including MRI and FDG-PET, tau-PET for FTLD, dopamine transport scan for LBD/PDD, and diffusion tensor imaging for VaD.142 Single-photon emission computed tomography studies are desirable for differentiating dementia subtypes particularly where PET may not be available and use of PiB for in vivo imaging of amyloid may be difficult.180

In Africa, there are limited datasets on imaging and fluid biomarkers. Africa lags in these advances due to lack of investments in relevant research infrastructure and expertise and the high cost of these advanced modalities. Nevertheless, there is a ray of hope on the horizon as efforts are beginning to yield fruits. Global brain atrophy and medial temporal lobe atrophy on MRI were significantly associated with cognitive impairment in a cohort of Nigerian stroke survivors181 while MRI-determined thinning of the corpus callosum was associated with central nervous system disease severity and reduced immunity in a cohort of South African children living with HIV.182 Other studies have evaluated the role of CSF-based biomarkers,183 and peripheral blood cell biomarkers in HIV-associated neurocognitive disorders.97 Muscle strength measured using handgrip strength has been considered a biomarker of MCI in LMICs.184

4 | COVID-19 AND DEMENTIA IN AFRICA

The corona virus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a pandemic of current global proportions and importance.189 It is generally known that individuals living with cognitive impairment and dementia are particularly susceptible to the viral infection because of their age, coexisting morbidities, immune senescence, and reduced ability to adhere to the preventive protocols.190,191 In Africa, there have been > 2.7 million COVID-19 cases and long-term consequences are of particular concern (www.afro.who.int). Mortality rates are also very high in this population even though African data are sparse.192,193 The peculiar challenges of COVID-19 and the elderly in Africa are premised on further erosion of the social support structure by social distancing, weak and fragile health-care systems, worsening poverty, and poor health-care financing.191–193 The situation is further aggravated by the dependence on caregivers for the performance of activities of daily living. This is fraught with the risk of infection with COVID-19 of both the person living with dementia as well as the caregiver. Social distancing also predisposed to exacerbations of neuropsychiatric symptoms like anxiety, agitation, and depression.194 To mitigate these challenges in the African context, social connection and interactions= needs to be maintained with older adults, persons living with dementia, and their caregivers in spite of “spatial distancing.” Family members and health-care providers can keep in touch through various digital technologies including video and audio phone calls, WhatsApp, etc.192 In the wake of the 2020 lockdown, unique telemedicine-based care models of care have been developed to meet the care needs of elderly Africans. In Nigeria for instance, a “Care in Place” policy was implemented in a pioneering geriatric center. This involved the provision of home-based care for ambulatory geriatric patients to prevent avoidable hospital visits and with the attendant risk of infection with the virus.195 Other recommendations from the Lancet Commission194 on dementia prevention, treatment, and care and dementia experts190 are generally applicable within the African context.

3.6 | Integrative transomics and precision medicine for dementia

Emerging insights from progress in multi-omics research suggest that dysregulation of molecular pathways at multiple levels, including the genome, epigenome, transcriptome, proteome, and the metabolome in response to numerous risk factors and triggers are involved in the neuropathological cascades that ultimately result in cognitive impairment and dementia.185,186 Thus, an integrative approach involving the exploration of sociodemographic, lifestyle, clinical, imaging, genetic, epigenetic, fluid biomarkers, and pathologic substrates of cognitive decline and dementia in diverse populations including indigenous Africans will provide useful insights into new pathways, processes, and networks; potential identification and characterization of novel biomarkers for prevention, risk profiling, early detection, diagnosis, prognosis; and treatment of cognitive disorders in a precision medicine framework.187,188

5 | THE AFRICAN DEMENTIA CONSORTIUM

The broad aim of the African Dementia Consortium (AfDC) is to bring together African dementia researchers in a multidisciplinary framework and generate clinical, cognitive, socioeconomic, neuroimaging, genomic, and biomarker data to improve the phenotypic characterization of dementia in Africans. The network will also identify novel biomarkers and interventions for prevention and treatment. The AfDC will further foster the translation of evidence to policy and practice and contribute to efforts to reduce the burden of dementia among Africans and African ancestry populations in diaspora, and ultimately contribute to the reduction of the global burden of dementia.

In order of priority, AfDC will focus on research areas, including (1) epidemiological studies to define trends in prevalence, incidence, and risk factors for dementia in Africa; (2) genetic studies to unmask novel variants that predispose to ADRD in African populations and
also increase African participation in global genomic studies including trans-ancestry meta analyses in dementia; (3) detection of unique biomarkers for dementia; (4) conduct of dementia clinical trials involving African populations; (5) capacity building and networking among dementia researchers living or working in Africa particularly early-career investigators; (6) facilitation of translational dementia research; (7) promotion of implementation science for translation of research evidence to practice and policy in Africa; and (8) training and education of the next generation of research leaders. The consortium will build effective synergies through collaborative research networks with researchers within Africa and with partners from North America, Latin America, Europe, Asia, and other regions of the world.

6 | CONCLUSION

It is imperative that we invest resources to better reduce the current vast gaps in knowledge regarding AD and other dementias in the African continent. The aging of the population makes this an economic and social, as well as a moral and ethical imperative. Furthermore, undertaking further genetic, biomarker, and pathological studies in this genetically and environmentally diverse region promises to lead to an improved understanding of the biology of AD that will benefit individuals and populations all over the world and further promote effective prevention, treatment, and care as recently outlined by the Lancet Commission on Dementia.194 Equity in access to dementia diagnosis, treatment, and access to care as well as dementia prevention strategies should remain core to the future efforts engaged in dementia science and care in Africa.

ACKNOWLEDGMENTS

ROA is supported by the UK Royal Society/African Academy of Sciences FLAIR Grants FLR/R1/191813 and FCG/R1/201034, and GCRF Networking Grant from the UK Academy of Medical Sciences and Global Brain Health Institute/Alzheimer’s Association/Alzheimer’s Society UK Grant GBHI ALZ UK-21-724204. ROA, MG, LM-M, KR, and KB are Senior Atlantic Fellows of the Global Brain Health Institute. ROA, MOO, AA, and FSS are also supported by Grants U54HG007479 and U01HG010273 from the National Institutes of Health (NIH), USA as part of the H3Africa Consortium. MOO, ROA FSS, and AA are further supported by NIH grant R01NS107900. SS is supported by NIH grants U01 AG052409 and R01 AG054076 RNK's research on elderly post-stroke dementia has been supported by the Medical Research Council, RCUK Newcastle Centre for Brain Ageing and Vitality (MRC G0500247), Medical Research Council (UK), Alzheimer’s Research UK, the Dunhill Medical Trust UK, and the Newcastle National Institute for Health Research Biomedical Research Centre in Ageing and Age-Related Diseases, Newcastle upon Tyne Hospitals National Health Service Foundation Trust.

CONFLICTS OF INTEREST

All authors have no conflicts of interest related to this article.

AUTHOR CONTRIBUTIONS

ROA conceptualized and developed the outline of the article. ROA, JY, and AO researched the data for the article and wrote the first draft. RNK and AO reviewed and edited drafts of the article. All authors provided substantial intellectual inputs into, and revised drafts of the article and approved the final version of the article.

REFERENCES


SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.